Oruka Therapeutics (ORKA) vs Spyre Therapeutics (SYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Spyre Therapeutics (SYRE) has outperformed Oruka Therapeutics (ORKA) over the past year, gaining 304.8% versus a gain of 221.4%. Over five years, ORKA leads with a +145.3% price change compared with -58.1% for SYRE. Spyre Therapeutics is the larger company by market cap ($7.91 billion vs $5.44 billion), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ORKA | SYRE |
|---|---|---|
| Share price | $82.11 | $85.69 |
| Market cap | $5.44B | $7.91B |
| 1-day change | +6.25% | +7.25% |
| YTD return | +170.90% | +161.57% |
| 1-year return | +221.37% | +304.77% |
| 5-year return | +145.25% | -58.10% |
| EPS (TTM) | $-2.04 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-105.43M | $-155.20M |
| 52-week high | $115.52 | $110.18 |
| 52-week low | $24.46 | $18.12 |
| Distance from 52-week high | -28.92% | -22.22% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +88.77% | +40.28% |
| Average volume | 902.84K | 1.22M |
| Shares outstanding | 66.21M | 92.29M |
| Employees | 68 | 125 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SYRE has outperformed ORKA by 83.4 percentage points over the past year.
About Oruka Therapeutics
ORKA stock →Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
Healthcare · Biotechnology · 68 employees
About Spyre Therapeutics
SYRE stock →Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Healthcare · Biotechnology · 125 employees
ORKA vs SYRE FAQ
Which is bigger, Oruka Therapeutics or Spyre Therapeutics?
Spyre Therapeutics (SYRE) is larger, with a market capitalization of $7.91B compared with $5.44B for Oruka Therapeutics (ORKA).
Which stock has performed better over the past year, ORKA or SYRE?
SYRE returned +304.77% over the past 12 months, compared with +221.37% for ORKA (price return, excluding dividends). Past performance does not predict future results.
Are Oruka Therapeutics and Spyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.